Common questions about Эскапел (FAQ)
Q: Is Эскапел the same as the morning-after pill?
A: Yes. Эскапел is the brand name for a product that contains levonorgestrel 1.5 mg, which is a formulation internationally recognized and commonly referred to by users as the emergency contraceptive pill or 'morning-after pill.' Official sources classify it as an oral emergency contraceptive.
Q: What is the difference between Эскапел and Postinor?
A: Regulatory registries indicate that both Эскапел and Postinor contain the same single active substance, levonorgestrel, which is used for emergency contraception. These are different brand names used to market the same active ingredient in various global regions.
Q: How long might side effects from Эскапел typically last?
A: Official patient information often describes common side effects such as headache, nausea, and dizziness as generally mild and temporary. These effects typically begin to resolve within a few days after the tablet is taken.
Q: Can taking Эскапел affect the next menstrual period?
A: Yes, regulatory documents indicate that the medicine may alter the timing and nature of the next period. It is possible for the period to be delayed by a few days, or in some cases, it may occur earlier than expected.
Q: Is it common for bleeding or spotting to occur after using Эскапел?
A: According to official product information, it is listed as a very common side effect to experience irregular bleeding or spotting between the time the drug is taken and the next expected period.
Q: Are there any common medicines that are known to interact with Эскапел?
A: Yes. Regulatory sources note that medicines and supplements that induce liver enzymes (which speed up the clearance of the drug) can reduce its effectiveness. This includes certain antiepileptics, anti-infectives like rifampicin, and the herbal product St. John's wort.
Q: Does alcohol consumption affect how Эскапел works?
A: Official regulatory documents and patient instructions do not provide specific instructions or warnings concerning the consumption of alcohol and its potential effect on the efficacy of the medicine.
Q: Can a woman who is breastfeeding use Эскапел?
A: The active ingredient, levonorgestrel, is secreted into breast milk. Regulatory information typically discusses strategies to minimize infant exposure, such as taking the tablet immediately after a feed and then taking a break from breastfeeding, with guidance from a healthcare provider.
Q: Are there any known issues with using Эскапел for women with a history of liver conditions?
A: Official warnings state that the drug is generally not recommended for women with severe liver disease or severe hepatic dysfunction. This is because these conditions may impair the body's ability to process and clear the active substance.
Q: What are the most commonly reported side effects of Эскапел?
A: Official documents list very common side effects as including headache, nausea, fatigue (tiredness), lower abdominal pain, and menstrual disturbances (irregular bleeding).
Q: Is abdominal pain a common experience after taking Эскапел?
A: Yes, lower abdominal pain is classified in official regulatory documents as a very common side effect, meaning it may affect more than 1 in 10 people.
Q: Can Эскапел cause changes in mood or feelings?
A: Yes, official reports, including post-marketing experience data, have noted changes such as mood alterations and reports of depressed mood as possible adverse reactions.
Q: Is there any research about the long-term effects of using Эскапел repeatedly?
A: Regulatory documents state that this drug is not intended for routine use as a primary contraceptive method. Therefore, there is limited data and official guidance on the safety themes or effects related to the long-term or repeated use of this medicine.
Q: Does Эскапел protect against sexually transmitted infections?
A: No. Official documents contain a clear statement that the drug does not protect against HIV/AIDS or other sexually transmitted infections.
Q: Is it still appropriate to use Эскапел if there is uncertainty about the timing of the last period?
A: The medicine is contraindicated (should not be used) if a woman has a known or suspected pregnancy. Official guidance emphasizes that if the menstrual period is overdue, pregnancy must be ruled out before the tablet is taken.
Q: Can taking Эскапел affect fertility in the future?
A: The medicine works acutely to delay or inhibit ovulation. Official regulatory information states there is no known long-term data to suggest that taking this emergency contraceptive has any impact on a person's future fertility.
Q: What are the reasons someone might not be able to use Эскапел?
A: Official contraindications generally include a known or suspected pregnancy or a known hypersensitivity (allergy) to levonorgestrel or any of the inactive ingredients in the product.
Q: Can Эскапел be bought without a prescription in some places?
A: The availability of the drug depends on local regulatory jurisdiction. In many countries, the active substance is available as an over-the-counter (OTC) medicine without a prescription, though it may be subject to minimum age requirements.
Q: How should Эскапел be stored to maintain its quality?
A: Official storage instructions typically advise keeping the medicine below a specific temperature (often 25 C or 30 C), protecting it from light, and storing it in its original packaging.
Q: Is it possible for Эскапел to fail to work?
A: Yes, official clinical efficacy data indicates the drug will not prevent pregnancy in every instance. The medicine is not 100% effective, and its potential effectiveness decreases the longer the time interval is after unprotected intercourse.
Q: Can using Эскапел cause a headache?
A: Yes, headache is listed as a very common side effect in official regulatory documents.
Q: Are there any known interactions between Эскапел and herbal supplements?
A: Yes, the herbal product St. John's wort (Hypericum perforatum) is specifically documented in regulatory warnings as an enzyme inducer that can potentially reduce the concentration and effectiveness of the drug.
Q: What should be expected from the next period after using Эскапел?
A: The next period is usually expected around the normal time, but it may occur earlier or later than usual. Official guidance notes that if the period is delayed by more than 7 days or is unusually light or heavy, this is a trigger for seeking medical evaluation.
Q: What are the contraindications for using Эскапел?
A: Contraindications, as listed in official documentation, include a known or suspected pregnancy and known hypersensitivity (allergy) to the active substance (levonorgestrel) or any of the excipients.
Q: Is it normal to feel tired or dizzy after using Эскапел?
A: Yes. Fatigue (tiredness) is officially listed as a very common side effect, and dizziness is listed as a common side effect in regulatory documents.
Q: Can Эскапел be used by women under the age of 18?
A: Regulatory access rules vary by country. In some regions, the drug is available over-the-counter (OTC) for all women of childbearing potential, while in other regions, prescription requirements or age limits may apply to those under 18.
Q: What if a user is taking regular medication for epilepsy—can they still use Эскапел?
A: Official documents warn that certain antiepileptic medicines (anticonvulsants) are known enzyme-inducers that can reduce the drug's effectiveness. The use of these medicines may require alternative emergency contraceptive methods or dose adjustments, as noted in official prescribing information for users of enzyme-inducing agents.
Q: Can Эскапел interfere with the effectiveness of long-term contraceptives?
A: After taking emergency contraception, a woman can generally continue to use her regular hormonal contraception. Official guidance mentions that a barrier method (such as a condom) may be needed until the next period, as the medicine does not offer continuous protection.
Q: What regulatory bodies have approved the use of Эскапел?
A: The active substance, levonorgestrel (1.5 mg), is approved by numerous government drug agencies worldwide, including the EMA (European Medicines Agency) and the FDA (U.S. Food and Drug Administration), among other national bodies.
Q: Does Эскапел affect hormonal balance in the long term?
A: The medicine is a single, acute dose and is not intended for routine use. Regulatory information does not contain long-term safety data to assess the effects of repeated use on hormonal balance.
Q: Are there any warnings about allergic reactions to Эскапел?
A: Yes. Known hypersensitivity (allergy) to the active substance or any of the product's ingredients is listed as a contraindication. Allergic reactions have also been noted in official post-marketing reports.
Q: How long does the active ingredient of Эскапел stay in the body?
A: Pharmacokinetic data available in official product information shows that the active substance, levonorgestrel, has an elimination half-life that is officially cited as being approximately 24 to 26 hours.
Q: Can Эскапел interact with antibiotics?
A: Official documents warn that certain anti-infective agents, such as the antibiotic Rifampicin, can significantly reduce the effectiveness of the drug due to liver enzyme induction.
Q: Is there a maximum number of times Эскапел can be used in a year?
A: The medicine is an acute emergency measure. Regulatory documents state it is not intended for routine use and repeated administration within a single cycle is generally not advisable due to the potential for cycle disturbance. No specific annual limit is defined in official documents.
Q: What kind of research supports the safety profile of Эскапел?
A: The safety profile is supported by clinical trials that monitor adverse effects and by official post-marketing surveillance data. This evidence demonstrates that the drug is generally well-tolerated and that serious adverse effects are rare.
Q: Does the packaging of Эскапел include any patient information leaflets?
A: Yes. In line with regulatory requirements in most jurisdictions, the product is packaged with a patient information leaflet (or Summary of Product Characteristics) that includes instructions, important safety warnings, and lists of possible side effects.
